Free Trial

Geron (GERN) Competitors

Geron logo
$1.24 -0.05 (-3.88%)
Closing price 04:00 PM Eastern
Extended Trading
$1.28 +0.04 (+3.15%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GERN vs. ALKS, LGND, FOLD, BCRX, CLDX, DVAX, INVA, MNKD, NVAX, and OPK

Should you be buying Geron stock or one of its competitors? The main competitors of Geron include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Innoviva (INVA), MannKind (MNKD), Novavax (NVAX), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry.

Geron vs. Its Competitors

Alkermes (NASDAQ:ALKS) and Geron (NASDAQ:GERN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Alkermes presently has a consensus target price of $40.92, suggesting a potential upside of 40.03%. Geron has a consensus target price of $4.61, suggesting a potential upside of 271.86%. Given Geron's higher probable upside, analysts clearly believe Geron is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.83
Geron
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.60

In the previous week, Alkermes had 6 more articles in the media than Geron. MarketBeat recorded 14 mentions for Alkermes and 8 mentions for Geron. Alkermes' average media sentiment score of 0.97 beat Geron's score of 0.92 indicating that Alkermes is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alkermes
5 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Geron
2 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alkermes has a net margin of 23.30% compared to Geron's net margin of -119.54%. Alkermes' return on equity of 27.52% beat Geron's return on equity.

Company Net Margins Return on Equity Return on Assets
Alkermes23.30% 27.52% 17.98%
Geron -119.54%-47.86%-26.78%

Alkermes has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, Geron has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

95.2% of Alkermes shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 4.4% of Alkermes shares are held by insiders. Comparatively, 7.4% of Geron shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.56B3.09$367.07M$2.0913.98
Geron$76.99M10.26-$174.57M-$0.21-5.90

Summary

Alkermes beats Geron on 12 of the 16 factors compared between the two stocks.

Get Geron News Delivered to You Automatically

Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GERN vs. The Competition

MetricGeronMED IndustryMedical SectorNASDAQ Exchange
Market Cap$821.62M$2.96B$5.54B$9.41B
Dividend YieldN/A2.46%3.75%4.03%
P/E Ratio-5.908.2821.0120.09
Price / Sales10.26303.17433.8199.01
Price / CashN/A42.5936.1658.27
Price / Book2.707.678.125.65
Net Income-$174.57M-$55.28M$3.25B$257.91M
7 Day Performance-6.06%2.50%0.97%2.09%
1 Month Performance-20.00%11.70%7.36%11.13%
1 Year Performance-73.45%4.89%31.31%18.40%

Geron Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GERN
Geron
3.46 of 5 stars
$1.24
-3.9%
$4.61
+271.9%
-72.9%$821.62M$76.99M-5.9070News Coverage
ALKS
Alkermes
4.8084 of 5 stars
$29.23
+1.3%
$40.00
+36.8%
+19.3%$4.82B$1.56B13.991,800News Coverage
Analyst Forecast
LGND
Ligand Pharmaceuticals
3.5334 of 5 stars
$113.76
-0.7%
$146.14
+28.5%
+36.1%$2.19B$167.13M-15.9880
FOLD
Amicus Therapeutics
4.1574 of 5 stars
$6.05
-0.8%
$16.22
+168.1%
-40.7%$1.86B$528.29M-67.21480News Coverage
Positive News
Analyst Upgrade
BCRX
BioCryst Pharmaceuticals
4.3926 of 5 stars
$8.76
-2.0%
$16.70
+90.6%
+19.7%$1.83B$450.71M-33.69530Positive News
Analyst Revision
CLDX
Celldex Therapeutics
2.4484 of 5 stars
$20.94
-4.8%
$50.11
+139.3%
-40.8%$1.39B$7.56M-7.76150Positive News
DVAX
Dynavax Technologies
4.3821 of 5 stars
$10.30
+0.3%
$24.00
+133.0%
+0.0%$1.24B$277.25M-19.81350
INVA
Innoviva
4.0829 of 5 stars
$18.91
-1.6%
$55.00
+190.9%
+13.9%$1.19B$369.84M-18.72100Analyst Revision
Gap Up
MNKD
MannKind
2.6384 of 5 stars
$3.54
-1.7%
$10.33
+191.9%
-32.8%$1.08B$285.50M35.40400News Coverage
Analyst Upgrade
Insider Trade
Analyst Revision
NVAX
Novavax
4.3314 of 5 stars
$6.61
-2.8%
$17.00
+157.2%
-55.8%$1.07B$682.16M2.491,990
OPK
OPKO Health
4.0156 of 5 stars
$1.34
-1.5%
$2.75
+105.2%
-2.8%$1.06B$713.10M-19.142,997Positive News

Related Companies and Tools


This page (NASDAQ:GERN) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners